Nov 22, 2025 · 44 min
AstraZeneca bets on U.S. expansion as markets test growth stocks
Mad Money w/ Jim Cramer 11/21/25
The episode connects a volatile holiday-week market with the investment case for dividends, growth, earnings, and pharmaceutical expansion.
- 1Cramer weighs dividend protection against growth stocks as investors navigate Thanksgiving-week volatility.
- 2AstraZeneca CEO Pascal Soriot outlines U.S. investment, drug-pricing plans, and risks across the company’s cancer pipeline.
- 3The S&P oscillator becomes Cramer’s tool for judging selling pressure and identifying potential market bottoms.
Don't miss
Pascal Soriot explains how AstraZeneca plans to expand its U.S. footprint while lowering medicine costs without undermining biopharmaceutical innovation.
The brief
Cramer opens with the Thanksgiving-week market outlook, then uses viewer questions on Palantir, Goldman Sachs, and Costco to frame a volatile tape.
The stock debate turns to defense: dividends may cushion volatility, but Cramer argues that growth can remain the stronger protection when market conditions shift.
Oddity’s strong earnings and sharp pullback raise a valuation question, while Elf Beauty faces tariffs and short interest and Trade Desk faces Amazon’s pressure.
AstraZeneca CEO Pascal Soriot discusses the company’s multibillion-dollar Maryland investment, U.S. jobs, drug pricing, listing plans, and cancer pipeline risks.
Cramer closes by rejecting unprofitable names and explaining how the S&P oscillator can reveal when selling pressure may be exhausting itself.
What was said on this episode
27 statements · 19 positive · 8 negative
Zoom will report a decent quarter and may attract acquisition interest.
“I expect a decent quarter and then the adjacent talk about some company potentially buying Zoom.”
Listen at 2:12
Weak pending home sales would make a December Fed rate cut easier.
“I think we'll get what we want, which is weak pending home sales, and that makes it easier for the Fed to cut rates in December.”
Listen at 3:20
Analog Devices is not worth buying.
“I believe it's not worth buying”
Listen at 4:04
Investors should consider buying Texas Instruments.
“I'd like you to buy, well, at least think about buying the stock of Texas Instruments”
Listen at 4:07
Investors should own Dell Technologies before its earnings quarter.
“you need to own the stock ahead of the quarter”
Listen at 4:40
HP is highly exposed to commodity prices and will miss expectations.
“I think HP is genuinely hostage to commodity prices, and it won't be able to make the numbers.”
Listen at 4:48
Zscaler will report exceptionally strong results.
“when Zscaler reports, I bet records will be broken and you can break out the champagne.”
Listen at 5:04
Investors can buy Deere after earnings without missing much upside.
“I believe that you'll be able to buy shares in deer after the quarter without missing too much of the upside”
Listen at 6:04
Cramer recommends buying Palantir.
“I'm a buyer of Palantir.”
Listen at 6:31
Goldman Sachs’s Excel Sports Management deal is outside its strategic sweet spot.
“Goldman shouldn't do something that isn't exactly what is right in their sweet spot. And this one isn't.”
Listen at 7:28
Costco is attractive below $900 per share.
“I say Costco under $900 is a”
Listen at 8:16
Enbridge offers substantial downside protection.
“I think this one gives you a ton of downside protection.”
Listen at 11:30
Pfizer can use acquisitions to build a powerful drug pipeline.
“I think that Pfizer has the ability to use some of the businesses it's acquired in recent years to build up a powerful pipeline”
Listen at 13:10
Pfizer can easily cover its dividend with free cash flow.
“I think it can easily cover the dividend with their $15 billion in free cash flow.”
Listen at 13:58
Realty Income’s recent pullback is a buying opportunity.
“I think the stock's recent pullback is yes. a buying opportunity.”
Listen at 16:04
Cramer favors Enbridge, Pfizer, and Realty Income for yield protection.
“I like Enbridge, I like Pfizer, and I like letter O, Realty Income.”
Listen at 16:13
Oddity Technology is currently a compelling buying opportunity.
“right now, it's a compelling buying opportunity.”
Listen at 17:22
Il Makiage could reach $1 billion in sales by 2028.
“Imagine, please, that Il Makiage can reach $1 billion in sales by 2028.”
Listen at 19:50
Oddity Technology represents compelling value at current levels.
“At these levels, I think it represents a very compelling value.”
Listen at 23:12
Elf Beauty is materially exposed to tariff problems.
“it's just become one of those stocks that's a tariff problem.”
Listen at 23:40
Cramer does not endorse buying Elf Beauty at its current level.
“I'm afraid, literally, that I will get my head blown off if I say this is the level to buy it.”
Listen at 23:47
Trade Desk faces prohibitive competitive pressure from Amazon and hyperscalers.
“you can't go against the hyperscalers, particularly Amazon”
Listen at 24:35
Mettler Toledo is a good company to own.
“You got a good one there.”
Listen at 36:19
Opendoor is overvalued because it is not profitable.
“The stock is high given the fact that the company makes no money. I'm not a believer until it makes money.”
Listen at 37:08
Cramer cannot recommend Poet Technologies because its losses are excessive.
“It's losing too much money. It's losing too much money. And we're not. Remember, the era of magical investing is over. So I can't recommend a stock.”
Listen at 37:40
An S&P oscillator reading of minus five signals buying because markets are oversold.
“Minus 5 is when you have to start buying because we're oversold and due for a rebound.”
Listen at 39:38
Market indicators can identify an approaching market bottom.
“you can spot a bottom like this coming.”
Listen at 42:47
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Books & mentions
Some links are affiliate links — PodLume may earn a commission if you buy.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.